Study reveals 'significant disparities' between rich, poor countries in availability of cancer drugs
From 1990 to 2022, the number of new cancer drugs launched annually increased significantly in high-income countries, from 0.5 to over eight per year. However, in upper-middle-income countries, this increase was from 0.1 to 1.5, while lower-income countries saw minimal improvements, highlighting widening global disparities in cancer drug availability.